|
|
Volumn 65, Issue 4, 2008, Pages 619-620
|
|
Similarity of biotechnology-derived medicinal products: Specific problems and new regulatory framework
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BIOLOGICAL PRODUCT;
ERYTHROPOIETIN;
GRANULOCYTE COLONY STIMULATING FACTOR;
RECOMBINANT HUMAN INSULIN;
BIOEQUIVALENCE;
BIOTECHNOLOGY;
DRUG LEGISLATION;
DRUG MANUFACTURE;
DRUG MARKETING;
DRUG SAFETY;
EUROPEAN UNION;
LETTER;
POLICY;
PRIORITY JOURNAL;
PROTEIN GLYCOSYLATION;
RECOMBINANT DNA TECHNOLOGY;
ANIMALS;
BIOTECHNOLOGY;
DRUG INDUSTRY;
FEMALE;
HUMANS;
MALE;
PHARMACEUTICAL PREPARATIONS;
RISK MANAGEMENT;
TREATMENT OUTCOME;
|
|
EID: 40549112722
PISSN: 03065251
EISSN: 13652125
Source Type: Journal
DOI: 10.1111/j.1365-2125.2007.03062.x Document Type: Letter |
|
Times cited : (8)
|
|
References (0)
|
